Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Income tax expense (benefit) by Quarter
Income tax expense (benefit) ($M) ($M)
Gilead Sciences Income tax expense (benefit): $242M in Q2 2026, down 48.3% from a year earlier.
Latest, Q2 2026
242
Period ended Jun 30, 2026
Change on a year earlier
-48.3%
468 in Q2 2025
History
50 quarters
Since Q1 2014
Sources
41
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-06) ↗
Reported in Form 10-Q / 10-K Note 15 Income Taxes.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up income tax expense (benefit)
- Income (loss) before income taxes — Domestic U.S. ($M)–
- Income before income taxes — Foreign ($M)–
- U.S. federal statutory income tax rate (%)–
- Current income tax expense — Federal ($M)–
- Current income tax expense — State ($M)–
- Current income tax expense — Foreign ($M)–
- Deferred income tax expense (benefit) — Federal ($M)–
- Deferred income tax expense (benefit) — State ($M)–
- Deferred income tax expense (benefit) — Foreign ($M)–
- Deferred tax assets (DTA), gross before valuation allowance ($M)–
- Unrecognized tax benefits (UTB) — Ending gross balance ($M)–
Cite this data
StockData. (2026). Gilead Sciences Income tax expense (benefit) ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/tax-exp-tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.